MedTrace Logo

Clopidogrel for Acute Ischaemia of Recent Onset

NCT02776540 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2019-02-12

No results posted yet for this study

Summary

Evaluate the role of loading Clopidogrel in acute ischemic stroke in improving neurological outcome of stroke in cases patients will be non-eligible for, or declined, treatment with or intravenous thrombolysis with rTPA, rTPA is not available or thrombectomy.

Conditions

  • Ischemic Cerebrovascular Accident

Interventions

DRUG

Clopidogrel

there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel

DRUG

Aspirin

there's another group will receive 400 mg Aspirin

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Ramez R Moustafa, MD PhD MRCP · Department of Neurology, Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-01
Primary Completion
2019-02-01
Completion
2019-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02776540 on ClinicalTrials.gov